Refine by
Henlius Clinical Screening Trial Equipment & Supplies
6 equipment items found
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX14, recombinant anti-RANKL human monoclonal antibody injection, a denosumab biosimilar. It is potentially indicated for the treatment of postmenopausal women with OP at high risk for fracture. First subject has been doesd in the international multi-centre phase 3 clinical trial in China for the treatment of postmenopausal osteoporosis in women with high fracture ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX04-O, recombinant anti-VEGF humanised monoclonal antibody injection. It is indicated for wet age-related macular degeneration (wAMD). HLX04-O was granted Phase 3 clinical study approvals in Australia, the United States, Singapore and the EU countries such as Latvia, Hungary and Spanish. In April 2022, the first patient in Australia and Latvia was dosed in the global multicentre phase 3 ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX07, recombinant anti-epidermal growth factor receptor (EGFR) humanised monoclonal antibody injection independently researched and developed as biobetter. It was granted IND approvals to be evaluated in clinical trials in China and the United States. It demonstrated favorable safety and tolerability profile in a prospective, open-label, dose-escalation Phase 1 clinical study (HLX07FIH, ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX11, recombinant anti-HER2 domain II humanised monoclonal antibody injection, a pertuzumab biosimilar. It can be used in combination with trastuzumab and chemotherapy for adjuvant treatment and neoadjuvant treatment for patients with HER2-positive BC and HER2-positive mBC. The first subject has been dosed in multi-centre phase 3 clinical trial of HLX11 for the neoadjuvant therapy in patients ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX22, humanised IgG1 monoclonal antibody injection targeting human epidermal growth factor receptor-2 (HER2). First patient has been dosed in Phase 2 clinical trial to compare HLX22 in combination with trastuzumab and chemotherapy as first-line therapy for HER2-positive locally advanced or metastatic gastric cancer patients in Chinese ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
(serplulimab injection, anti-PD-1 mAb), company’s first self-developed innovative monoclonal antibody, was approved by the NMPA for the treatment of Microsatellite Instability-High (MSI-H) solid tumors in March 2022, providing an alternative treatment option for patients with MSI-H solid tumors. Henlius actively promotes HANSIZHUANG in conjunction with in-house products of the company and ...